Skip to main content Skip to navigation
Anti-HLA-DR APC
Product Details
Down Arrow Up Arrow


BD™
MHC class II antigen; HLA class II histocompatibility antigen
Human
Mouse IgG2a, κ
Human lymphoblastoid B-cell line RPMI 8866
Flow cytometry
50 μg/mL
5 μL
Phosphate buffered saline with gelatin and 0.1% sodium azide.
RUO (GMP)


Preparation And Storage

The antibody reagent is stable until the expiration date shown on the label when stored at 2°C to 8°C. Do not use after the expiration date. Do not freeze the reagent or expose it to direct light during storage or incubation with cells. Keep the outside of the reagent vial dry.

Do not use the reagent if you observe any change in appearance. Precipitation or discoloration indicates instability or deterioration.

347403 Rev. 1
Antibody Details
Down Arrow Up Arrow
L243

Anti–HLA-DR is intended for in vitro diagnostic use in the identification of cells expressing the HLA-DR antigen, using a BD FACS™ brand flow cytometer.

The flow cytometer must be equipped to detect light scatter and the appropriate fluorescence, and be equipped with appropriate software (such as BD CellQuest™, BD CellQuest™ Pro, BD FACSDiva™, or BD FACSCanto™ clinical software) for data acquisition and analysis. See your instrument user’s guide for instructions.

347403 Rev. 1
Format Details
Down Arrow Up Arrow
APC
Allophycocyanin (APC), is part of the BD family of phycobiliprotein dyes. This fluorochrome is a multimeric fluorescent phycobiliprotein with excitation maximum (Ex Max) of 651 nm and an emission maximum (Em Max) at 660 nm. APC is designed to be excited by the Red (627-640 nm) laser and detected using an optical filter centered near 660 nm (e.g., a 660/20 nm bandpass filter). Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
altImg
APC
Red 627-640 nm
651 nm
660 nm
347403 Rev.1
Citations & References
Down Arrow Up Arrow

Development References (31)

  1. Borowitz MJ, Gockerman JP, Moore JO, et al. Clinicopathologic and cytogenic features of CD34 (My 10)-positive acute nonlymphocytic leukemia. Am J Clin Pathol. 1989; 91:265-270. (Biology).
  2. Brodsky FM. A matrix approach to human class II histocompatibility antigens: reactions of four monoclonal antibodies with the products of nine haplotypes.. Immunogenetics. 1984; 19(3):179-94. (Biology). View Reference
  3. Centers for Disease Control. Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in healthcare settings. MMWR. 1988; 37:377-388. (Biology).
  4. Clinical Applications of Flow Cytometry: Quality Assurance and Immunophenotyping of Lymphocytes: Approved Guideline. H42-A2. 2007. (Biology).
  5. Clinical and Laboratory Standards Institute. 2005. (Biology).
  6. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Rothe G, Schmitz G. Leukemia. 1996; 10:877-895. (Biology).
  7. Dorak MT, Lawson T, Machulla HK, Darke C, Mills KI, Burnett AK. Unravelling an HLA-DR association in childhood acute lymphoblastic leukemia. Blood. 1999; 94:694-700. (Biology).
  8. Edwards JA, Durant BM, Jones DB, Evans PR, Smith JL. Differential expression of HLA class II antigens in fetal human spleen: relationship of HLA-DP, DQ, and DR to immunoglobulin expression.. J Immunol. 1986; 137(2):490-7. (Biology). View Reference
  9. Engleman EG, Warnke R, Fox RI, Dilley J, Benike CJ, Levy R. Studies of a human T lymphocyte antigen recognized by a monoclonal antibody.. Proc Natl Acad Sci USA. 1981; 78(3):1791-5. (Biology). View Reference
  10. Geisberg M, Stole E, Knowles R. Knapp W, Dörken B, Gilks WR, et al, ed. Leucocyte Typing IV: White Cell Differentiation Antigens. New York, NY: Oxford University Press Inc; 1989:729-736.
  11. Hulstaert F, Hannet I, Deneys V, et al. Age-related changes in human blood lymphocyte subpopulations, II: Varying kinetics of percentage and absolute count measurements. Clin Immunol Immunopathol. 1994; 70:152-158. (Biology).
  12. Jackson AL, Warner NL. Rose NR, Friedman H, Fahey JL, ed. Manual of Clincial Laboratory Immunology, Third Edition. Washington DC: American Society for Microbiology; 1986:226-235.
  13. Lampson LA, Levy R. Two populations of Ia-like molecules on a human B cell line.. J Immunol. 1980; 125(1):293-9. (Biology). View Reference
  14. Lazarchick J, Hopkins M. HLA-DR negative acute non-lymphocytic leukemia. Ann Clin Lab Sci. 1998; 28:150-152. (Biology).
  15. Levacher M, Tallet S, Dazza MC, Dournon E, Rouveix B, Pocidalo JJ. T activation marker evaluation in ARC patients treated with AZT. Comparison with CD4+ lymphocyte count in non-progressors and progressors towards AIDS.. Clin Exp Immunol. 1990; 81(2):177-82. (Biology). View Reference
  16. Macedo A, Orfao A, Gonzalez M, et al. Immunological detection of blast cell subpopulations in acute myeloblastic leukemia at diagnosis: implications for minimal residual disease studies. Leukemia. 1995; 9:993-998. (Biology).
  17. O'Gormon MRG, Millard DD, Lowder JN, Yogev R. Lymphocyte subpopulations in healthy 1–3-day-old infants. Cytometry. 1998; 34:235-241. (Biology).
  18. Paietta E, Andersen J, Gallagher R, et al. The immunophenotype of acute promyelocytic leukemia (APL): an ECOG study. Leukemia. 1994; 8:1108-1112. (Biology).
  19. Porwit-MacDonald A, Janossy G, Ivory K, et al. Leukemia-associated changes identified by quantitative flow cytometry, IV: CD34 overexpression in acute myelogenous leukemia M2 with t(8;21). Blood. 1996; 87:1162-1169. (Biology).
  20. Schuerch CI, Fleetwood M, Glidewell O, Goodspeed N, Maier B. Lymphocyte subsets and activation antigens in a reference population: a flow cytometric study using single and double antibody staining. Immunol Invest. 1987; 16:345-360. (Biology).
  21. Shahabuddin S. Quantitative differences in CD8+ lymphocytes, CD4/CD8 ratio, NK cells, and HLADR+- activated T cells of racially different male populations. Clin Immunol Immunopathol. 1995; 75:168-170. (Biology).
  22. Stelzer GT, Marti G, Hurley A, McCoy PJ, Lovett EJ, Schwartz A. US-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry. 1997; 30:214-230. (Biology).
  23. Stites DP, Casavant CH, McHugh TM, et al. Flow cytometric analysis of lymphocyte phenotypes in AIDS using monoclonal antibodies and simultaneous dual immunofluorescence.. Clin Immunol Immunopathol. 1986; 38(2):161-77. (Biology). View Reference
  24. Terstappen LW, Hollander Z, Meiners H, Loken MR. Quantitative comparison of myeloid antigens on five lineages of mature peripheral blood cells. J Leukoc Biol. 1990; 48(2):138-148. (Biology). View Reference
  25. Tollerud DJ, Ildstad ST, Morris Brown L, et al. T-cell subsets in healthy teenagers: transition to the adult phenotype. Clin Immunol Immunopathol. 1990; 56:88-96. (Biology).
  26. Tomkinson BE, Wagner DK, Nelson DL, Sullivan JL. Activated lymphocytes during acute Epstein-Barr virus infection.. J Immunol. 1987; 139(11):3802-7. (Biology). View Reference
  27. Vaughan WP, Civin CI, Weisenburger DD, et al. Acute leukemia expressing the normal human hematopoietic stem cell membrane glycoprotein CD34 (MY10). Leukemia. 1988; 2:661-666. (Biology).
  28. Venditti A, Del Poeta G, Stasi R, et al. Triple immunofluorescence evaluation of CD15, CD34 and class II expression by flow cytometry in normal and leukemic bone marrows. Haematologica. 1993; 78:359-363. (Biology).
  29. Warnke R, Miller R, Grogan T, Pederson M, Dilley J, Levy R. Immunologic phenotype in 30 patients with diffuse large-cell lymphoma.. N Engl J Med. 1980; 303(6):293-300. (Biology). View Reference
  30. Warnke RA, Levy R. Detection of T and B cell antigens with hybridoma monoclonal antibodies: a biotinavidin-horseradish peroxidase method. J Histochem Cytochem. 1980; 28:771-776. (Biology).
  31. Zipf TF, Fox RI, Dilley J, Levy R. Definition of the high-risk acute lymphoblastic leukemia patient by immunological phenotyping with monoclonal antibodies.. Cancer Res. 1981; 41(11 Pt 2):4786-9. (Biology). View Reference
View All (31) View Less
347403 Rev. 1

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. 

 

Although not required, these products are manufactured in accordance with Good Manufacturing Practices.